



Preparing and submitting an application for *in situ* substances

ECHA Biocides Stakeholders' Day September 1, 2016



MANAGEMENT

PRODUCT

SUSTAINABILITY SERVICES

Support for individual or grouped companies applying or for a family or individual biocidal products authorisation - EU or national





ERM

JSC

TECHNICAL EXPERTISE

Scientific experts delivering regulatory and testing strategy services, providing Chemical, Toxicological and Exotoxicological expertise


- Approval of active substances
- Authorisation of biocidal products

Strong, globally connected team focused on providing both local and global knowledge of market drivers and regulatory landscape

This unique combination ERM-ReachCentrum-JSC provides a wealth of knowledge and experience covering a wide range of product types and regulatory procedures to support clients through the value chain




CONTENT



IN SITU SUBSTANCES

 Substances that are generated from one or more precursors at the place of use



ARTICLE 3((1)(A)) OF BPR 528/2012

The definition of biocidal product confirms that:

- The supply of a precursor with the intention to generate an in situ biocide
- Biocides generated from ambient precursors that are not supplied
- Falls under the *in situ* generated substance

IN SITU SUBSTANCE CONT.

- Agreement between MSCAs and the European Commission
- For all substances generated *in situ*, the active substance must be defined by reference to the precursor(s) supported in the dossier and to the substance generated




DOSSIER PREPARATION

For in situ generated active substance, the dossier will need to cover data on both the in situ substance and the precursor(s), as well as other relevant substances in terms of generating the active



DATA ANALYSIS

Where the active substance is generated in situ then 5-batch analysis data on the precursors and the active substance itself is required



DESCRIPTION OF THE METHOD OF APPLICATION

If an apparatus is used to produce the active substance in situ and to dose it directly, information should be provided on safety measures concerning over and under dosing




RISK ASSESSMENT


For in situ generated active substance, the risk assessment includes also the possible risks from the precursor(s)




TECHNICAL STEPS IN APPROVAL/AUTHORISATIONS PROCESSES




COLLECT DATA



DATA GAP ANALYSIS




DERIVING HAZARDS AND THRESHOLDS




Derive toxicity threshold using the toxicity data i.e. the level that is not dangerous to humans or environment


ASSESS EFFICACY



ASSESS EXPOSURE



CHARACTERISE THE RISK



TECHNICAL DOSSIER

Step 1

Define Reference Substances Step 2


Construct Precursor Dataset (s) Step 3

Make in situ Substance Dataset Step 4


Product/Mixture Dataset(s)

Step 5


Generate Dossier




IUCLID 6




IUCLID 6




IUCLID 6




R4BP3



R4BP3











Thank you for your attention

Magdalena Kornacka Project Manager REACH and BPR

Email: magdalena.kornacka@reachcentrum.eu

www.reachcentrum.eu www.erm.com www.jsci.co.uk